 Pharmacor --
March 2005
 You Need to Know
How will the recent withdrawal of duloxetine's new drug
application for treatment of stress urinary incontinence (SUI) in the United
States affect the future SUI market? Which developments in surgical techniques and devices have
thought-leading physicians identified as the cornerstones of current SUI
medical practice? How does patient willingness to consult physicians about SUI symptoms
affect the commercial success of pharmacotherapies?
Introduction
Stress urinary incontinence
(SUI) is a female-predominant condition that causes economic, social, and
physical hardship to those affected by it. To date, the management of SUI has
been dominated by nonpharmacological therapies: pelvic-floor-muscle rehabilitation
exercises, absorbent pads, and corrective surgeries. With the introduction of
new pharmacotherapy, expert clinicians interviewed by Decision Resources report
that treatment of SUI will soon expand the opportunity for
pharmacotherapy in this surgery-driven market. As a result, we anticipate that the
now-dormant market for SUI pharmacotherapies will experience dramatic change
over our ten-year forecast period.
Key Findings
 In 2003, the SUI prevalent population exceeded 43 million in the seven
major pharmaceutical markets we cover. Although the prevalent population will
grow modestly during the forecast period, the most significant demographic
change will be the almost sevenfold increase in the drug-treated population.
Effective pharmacotherapy remains the greatest unmet need in the
treatment of SUI. Physicians are eager for drugs that not only reduce the
number of daily incontinent episodes but are also effective enough to
completely stop incontinent episodes in a significant proportion of mild-to-moderate
SUI patients who are not candidates for or are unwilling to undergo
surgery.
The recent European launch of duloxetine (Eli
Lilly/Boehringer Ingelheim's Yentreve/Ariclaim) has provided a clinically
effective pharmaceutical treatment option for SUI. However, surgical techniques
used to treat SUI are both routine and effective, and most experts interviewed
are confident that surgery will remain the gold-standard treatment for SUI.
Why Buy This Report?
Explore how recent understanding of biochemical pathways has led
to the development of novel pharmacotherapies for SUI.
Discover the impact that duloxetine will have on the SUI market
and how it will fit into physicians' treatment algorithms.
Delve into the regional differences affecting sales in an
expanding pharmacotherapy market.
Learn the varied opinions and concerns of medical thought leaders
regarding the dynamics of the SUI treatment landscape over the 2003-2013 study period.
|
